Anti-Caveolin-1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution

Not available outside of the UK & Ireland.

Application

Anti-Caveolin-1 antibody produced in rabbit has been used in:immunoblotting immunofluorescence immunohistochemistry

Biochem/physiol Actions

Caveolin can simultaneously recognize GPI-linked proteins and interact directly with a number of caveolae associated downstream signaling molecules, such as H-Ras, hetero-trimeric G-proteins, annexin-II, epidermal growth factor receptor (EGFR), protein kinase C, src-family tyrosine kinases and nitric oxide synthase (NOS) isoforms. Caveolin-1 participates in angiogenesis and is expected to play a major role in the growth and evolution of cancer. It participates in glucose metabolism by controlling the expression of glucose transporters.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Caveolin, a 20-24 kDa integral transmembrane protein, has been identified as a principal component of caveolae membranes. Caveolin (also termed VIP21) exists in several isoforms termed caveolin-1, caveolin-2 and caveolin-3. Caveolin-1 (CAV1) (20- 22 kDa) can exist as two isoforms, caveolin-1α and -1β due to alternative splicing of the mRNA. Caveolin-1 and -2 have similar tissue distribution.

Immunogen

synthetic peptide corresponding to a region at the N-terminus of human caveolin-1 (amino acids 2-20).

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Specificity

The sequence is highly conserved in many species, e.g., identical in rat, mouse, bovine, and dog caveolin-1. The sequence is not found in caveolin-2 or caveolin-3.